

## Evaluation of the Hepatoprotective Effect of L-Ascorbate 1-(2-Hydroxyethyl)-4,6-Dimethyl-1,2-Dihydropyrimidine-2-One Upon Exposure to Carbon Tetrachloride

Vyshtakalyuk A., Nazarov N., Zobov V., Abdulkhakov S., Minnekhanova O., Semenov V., Galyametdinova I., Cherepnev G., Reznik V.

Kazan Federal University, 420008, Kremlevskaya 18, Kazan, Russia

---

### Abstract

© 2017, Springer Science+Business Media New York. Hepatoprotective properties of a new pyrimidine derivative — L-ascorbate 1-(2-hydroxyethyl)-4,6-dimethyl-1,2-dihydropyrimidine-2-one, synthesized on the basis Xymedon, were assessed in white rats exposed to CCl<sub>4</sub>. The compound under study administered prior to exposure to CCl<sub>4</sub> reduced the deviation of biochemical parameters from reference values and severity of structural and morphological changes in liver, when compared to the control. Hepatoprotective properties of the studied compound were more pronounced than those of Xymedon.

<http://dx.doi.org/10.1007/s10517-017-3610-8>

---

### Keywords

ascorbate, CCl<sub>4</sub>, hepatoprotectors, pyrimidine derivatives, toxic liver damage

### References

- [1] Vyshtakalyuk AB, Nazarov NG, Zueva IV, Lantsova AV, Minnekhanova OA, Busygin DV, Porfiriev AG, Evtyugin VG, Reznik VS, Zobov VV. Study of hepatoprotective effects of xymedon. *Bull. Exp. Biol. Med.* 2013;155(5):643-646.
- [2] Vyshtakaliuk AB, Zueva IV, Minnechanova OA, Reznik VS, Zobov VV, Nicolskyi EE, Nazarov NG, Porfiriev AG, Mayatina OV. The influence of the Xymedon preparation (Hydroxyethyl-dimethyl-dihydropyrimidine) on the rat liver recovery under toxic damage induced by carbon tetrachloride. *Doklady Biochem. Biophysics.* 2015;462(1):143-146.
- [3] Zobov VV, Nazarov NG, Vyshtakalyuk AB, Galyametdinova IV, Semenov VE, Reznik VS. Efficiency of new pyrimidine derivativs influence on physical working capacity of rats in the test "swimming to failure". *Ekol. Cheloveka.* 2015(1):28-35. Russian.
- [4] Myshkin VA, Enikeyev DA. Oxymethyluracil and experimental pathology of the liver. *Med. Vestn. Bashkortastana.* 2009;4(2):147-151. Russian.
- [5] Novikov VE, Klimkina EI. Pharmacology of hepatoprotectors. *Obzory po Klin. Farmakol. Lek. Ter.* 2005;4(1):2-20. Russian.
- [6] Pogorel'tsev VI, Garmonov SJ, Reznik VS, Shitova NS, Jakovleva AV. Patent RF No. 2316327. Ximedon as inductor of human liver microsomal oxidase activity. *Bull. No. 4.* Published February 10, 2008.
- [7] Manual on Experimental (Preclinical) Study of New Pharmacological Substances, Khabriev RU, ed. Moscow, 2005. P. 685. Russian.
- [8] Taouk AN, Fiodorov VN, Kunitsa ZA, Smirnov NA, Kotshneva NV. Comparative efficacy of drugs of different pharmacotherapeutic groups in experimental toxic hepatitis. *Ros. Med.-Biol. Vestn.* 2010(1):66-73. Russian.

[9] Krutikov VI, Ashkinazi RI. Patent US 6730787 B1. 2,4-Dioxo-5-arylideneimino-1,3-pyrimidines. Date of Patent May 04, 2004.